

World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime

- *From a sample of over 10,000 adults, 62% are worried that they may develop Alzheimer's disease and 91% believe the solution to tackling diseases lies in medical research¹*
- *79% are willing to take part in medical research but three-quarters (75%) have no idea how to get involved¹*
- *This World Alzheimer's Month, in association with Alzheimer's Disease International, Novartis, Amgen and Banner Alzheimer's Institute are raising awareness about how to get involved in Alzheimer's research*

Basel, September 17, 2018 – Novartis, Amgen and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), today announced results from the largest global survey to date investigating perceptions of Alzheimer's disease. Findings show that most adults (62%) are worried that they may develop Alzheimer's, while nearly the same proportion believe it is likely a cure will be developed in their lifetime (60%).¹ This World Alzheimer's Month, Novartis, Amgen, BAI and ADI are raising awareness about how volunteers can take part in clinical studies to benefit Alzheimer's research, potentially themselves and future generations.

Alzheimer's is the leading cause of dementia, a disease affecting 50 million people worldwide and this number is expected to triple by 2050.² The survey of more than 10,000 people across 10 countries revealed that 91% believe the solution to tackling diseases lies in medical research and 79% are willing to participate.¹ However, three-quarters (75%) have no idea how to get involved in medical research.¹ In addition, 78% of adults are willing to get genetically tested to identify their potential risk of developing Alzheimer's.¹

"At present, there is no cure and limited treatment options for Alzheimer's, but this survey clearly shows that people are willing to participate in research to help treat and to hopefully find a cure," said Paola Barbarino, Chief Executive Officer at ADI. "We need to demystify and remove awareness barriers to participation in medical research, making all suitable candidates aware of how they can get involved."

Worldwide, more than 400 clinical studies are recruiting in Alzheimer's.³ However, slow enrollment is a costly and common obstacle that undermines medical research.⁴ There is a need for more people to volunteer to advance scientific discovery.

"The results from this survey clearly demonstrate the need to raise awareness about clinical studies globally," said Pierre N. Tariot, MD, director of BAI and co-director of the Alzheimer's Prevention Initiative (API). "Aside from funding, the greatest challenge in finding a way to treat, slow, or prevent Alzheimer's is the recruitment and retention of study participants. Scientists are making great progress in the fight against this disease, but an estimated 80% of studies fail to meet recruitment goals on time, which delays critically important research."

September 2018 marks the 7th World Alzheimer's Month and represents a chance for people to raise awareness, fundraise and find out more about how they can participate in research. In addition to the global survey results, ADI will also launch their World Alzheimer Report 2018 entitled *The state of the art of dementia research: new frontiers*, which looks at the hopes and aspirations, the barriers and enablers to improving dementia research globally. More information on the report can be found here www.alz.co.uk/worldreport2018.

“Novartis thanks all the participants who took part in this important survey. We have served patients in Neuroscience for over 70 years and believe that a focus on prevention is vital to safeguard future generations,” said John Tsai, M.D., Global Head Drug Development and Chief Medical Officer for Novartis. “This survey highlights that greater awareness and support is needed. This is to ensure people have sufficient knowledge about clinical research studies to make a well-informed choice about getting involved, so that together we can reimagine Alzheimer’s care for the future.”

Novartis, Amgen and BAI are sponsors of the API’s Generation Program, which is evaluating investigational treatments to help prevent or delay the onset of Alzheimer’s. The Program is enrolling volunteers aged 60-75 who are at higher risk of developing Alzheimer’s but do not currently have or show signs of the disease. Information can be found at www.generationprogram.com. Learning about increased genetic risk as part of a clinical study can result in a unique emotional response; pre- and post-test genetic counselling is often recommended to help manage these responses and provide information on implications for the individual and their family.⁵

Information about clinical trials is widely available online and from local patient advocacy groups. Details of Alzheimer’s clinical studies can be found on the ADI website www.alz.co.uk/clinical-trials/find and the Alzheimer’s Prevention Registry www.endALZnow.org/. Studies can also be found within the ClinicalTrials.gov study database, <https://clinicaltrials.gov>, under the search criteria ‘Recruiting’ and ‘Alzheimer Disease’.

About the survey

The survey was conducted online by The Harris Poll on behalf of Novartis, Amgen and Banner Alzheimer’s Institute, among 10,095 adults 18+ living in Argentina, Canada, China, France, Germany, Italy, Japan, Spain, the UK and the US. The survey was conducted between July 25 and August 21, 2018. Figures for age by gender, income, education, race/ethnicity (Canada and US only), region, size of household, marital status, and employment status were weighted where necessary to bring them into line with their actual proportions in the population.

The Alzheimer’s Prevention Initiative (API) is an international collaborative research effort formed to launch a new era of Alzheimer’s prevention research. Led by Banner Alzheimer’s Institute, the API conducts prevention trials in cognitively healthy people at increased genetic risk for Alzheimer’s disease. It will continue to establish the brain imaging; biological and cognitive measurements needed to rapidly test promising prevention therapies and provide registries to support enrollment in future prevention trials. API is intended to provide the scientific means, accelerated approval pathway with the cooperation of the regulatory agencies and enrollment resources needed to evaluate the range of promising Alzheimer’s prevention therapies and find ones that work. For more information, go to www.alzheimerspreventioninitiative.com

About Amgen and Novartis Neuroscience Collaboration

In August 2015, Novartis entered into a global collaboration with Amgen to develop and commercialize pioneering treatments in the field of migraine and Alzheimer’s disease.

Disclaimer

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential”, “can”, “will”, “plan”, “expect”, “anticipate”, “look forward”, “believe”, “committed”, “investigational”, “pipeline”, “launch”, “pioneering”, or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other

things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 125,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit www.novartis.com

Novartis is on Twitter. Sign up to follow @Novartis at <http://twitter.com/novartis>
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

References

1. Data on file. August 2018.
2. Dementia fact sheet December 2017; World Health Organization: www.who.int/news-room/fact-sheets/detail/dementia. Accessed August 2018.
3. ClinicalTrials.gov:
<http://clinicaltrials.gov/ct2/results?recrs=ab&cond=Alzheimer+Disease&term=&cntry=&state=&city=&dist=>. Accessed August 2018.
4. *Clin Transl Sci*. 2015 Dec; 8(6): 647–654.
5. Genetic Alliance; District of Columbia Department of Health. Understanding Genetics: A District of Columbia Guide for Patients and Health Professionals. Washington (DC): Genetic Alliance; 2010 Feb 17. Chapter 4, Genetic Counselling. www.ncbi.nlm.nih.gov/books/NBK132139 August 2018.

###

Novartis Media Relations

Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com

Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com

Gonzalo Linares
Novartis Global Drug Development
Communications
+41 61 324 5117 (direct)
+41 79 386 7432 (mobile)
gonzalo.linares@novartis.com

Angela Fiorin
Novartis Global Pharma Communications
+ 41 61 324 8631 (direct)
+ 41 79 752 6955 (mobile)
angela.fiorin@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central

Samir Shah +41 61 324 7944

Pierre-Michel Bringer +41 61 324 1065

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

North America

Richard Pulik +1 212 830 2448

Cory Twining +1 212 830 2417